Forecasted Sales of Biosimilar Monoclonal Antibodies for Oncology Indications ... MarketWatch (press release) Biosimilar versions of rituximab (Biogen Idec/Roche/Chugai/Zenyaku Kogyo's Rituxan/MabThera) could be approved as early as 2013 in Europe. This approval will pave the way for biosimilar versions of other monoclonal antibodies including Bristol-Myers ... |
